ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1293

Synovitis and periarticular soft tissues abnormalities in childhood-onset systemic lupus erythematosus: an ultrasonography study
Abstract Number: 2285

Synovium-on-a-chip – Development of a Humanized Rheumatoid Arthritis Model that Mimics Disease and Patient Biological Heterogeneity
Abstract Number: 0214

Systematic Comorbidity Screening in Inflammatory Arthritis: The Experience of a Tertiary-Care Centre
Abstract Number: 1306

Systematic Literature Review of Digital Sleep Outcomes and Endpoints Used to Assess Rheumatoid Arthritis
Abstract Number: 1327

Systematic Review of Mobility in Rheumatoid Arthritis with Digitally Measured Objective Assessment
Abstract Number: 1384

Systematic Review of Therapies for Central Nervous System Manifestations in Sjögren’s Disease
Abstract Number: 2056

Systematic Review: Nutritional Interventions in Muscle Diseases
Abstract Number: 1619

Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
Abstract Number: 2130

Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom
Abstract Number: 1486

Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Abstract Number: 0615

Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
Abstract Number: 0709

Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven
Abstract Number: 1546

Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response
Abstract Number: 2662

Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-associated interstitial lung disease
Abstract Number: 1790

Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].